|
Federal
Register Notices > Notice
of Application >
Sigma Aldrich Research Biochemicals, Inc.
FR Doc E7-12971 [Federal Register: July 5, 2007 (Volume 72, Number 128)]
[Notices] [Page 36730-36731] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05jy07-118]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a)
of Title 21 of the Code of Federal Regulations (CFR),
this is notice that on March 29, 2007, Sigma Aldrich Research Biochemicals,
Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in schedule I
and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
Aminorex (1585)
|
I
|
|
Alpha-ethyltryptamine (7249)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxy methamphetamine (MDMA)(7405)
|
I
|
|
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470)
|
I
|
|
1-Benzylpiperazine (BZP) (7493)
|
I
|
|
Heroin (9200)
|
I
|
|
Normorphine (9313)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Nabilone (7379)
|
II
|
|
1-Phenylcyclohexylamine (7460)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Diprenorphine (9058)
|
II
|
|
Ecgonine (9180)
|
II
|
|
Levomethorphan (9210)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Metazocine (9240)
|
II
|
|
Methadone (9250)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Carfentanil (9743)
|
II
|
|
Fentanyl (9801)
|
II
|
The company plans to manufacture reference standards. Any other such
applicant and any person who is presently registered with DEA to manufacture
such a substance may file comments or objections to the issuance of the proposed
registration pursuant to 21 CFR 1301.33(a). Any such written comments or
objections being sent via regular mail should be addressed, in quintuplicate, to
the Drug Enforcement Administration, Office of Diversion Control, Federal
Register Representative (ODL), Washington, DC 20537, or any being sent via
express mail should be sent to Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis
Highway, Alexandria, Virginia 22301; and must be filed no later than September
4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-12971
Filed 7-3-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|
